Wolf, Andrea
Stratmann, Jan A.
Shaid, Shabnam
Niklas, Nicolas
Calleja, Alan
Ubhi, Harveen
Munro, Robin
Waldenberger, Daniela
Carroll, Robert
Daumont, Melinda J.
Penrod, John R.
Lacoin, Laure
Rohde, Gernot
Funding for this research was provided by:
Bristol Myers Squibb
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 9 August 2022
Accepted: 15 December 2022
First Online: 13 January 2023
Declarations
:
: The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices and applicable regulatory requirements. Ethics approval was obtained followed ethics committee review at Ethik-Kommission der Johann Wolfgang Goethe-Universität under reference number 274/18 and project number UCT-15-2020. As this was a retrospective observational study using anonymized patient data, informed consent was not required from patients and was waived by the aforementioned ethics committee (Ethik-Kommission der Johann Wolfgang Goethe-Universität).
: Not applicable.
: AW reports no conflicts of interest. JAS reports personal fees from Boehringer Ingelheim, AstraZeneca, Roche, Bristol Myers Squibb, Amgen, LEO Pharma, Novartis, and Takeda outside of the submitted work. SS reports no conflicts of interest. NN, AC, HU, and RM are employees of IQVIA. DW, RC, MJD, and JRP are employees of Bristol Myers Squibb; RC and JRP also report stock ownership in Bristol Myers Squibb. LL is an employee of Epi-Fit and was contracted (paid) as a consultant by Bristol Myers Squibb to support the I-O Optimise initiative. GR reports personal fees from AstraZeneca, Berlin Chemie, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer, and Vertex for consultancy during advisory board meetings and personal fees from AstraZeneca, Berlin Chemie, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer, and Vertex for lectures including service on speakers’ bureaus.